Jean-Luc M. Lemercier Sells 14,400 Shares of Edwards Lifesciences Co. (NYSE:EW) Stock

Edwards Lifesciences Co. (NYSE:EW) VP Jean-Luc M. Lemercier sold 14,400 shares of the business’s stock in a transaction on Wednesday, May 1st. The stock was sold at an average price of $84.21, for a total transaction of $1,212,624.00. Following the completion of the sale, the vice president now owns 173,849 shares in the company, valued at approximately $14,639,824.29. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link.

Edwards Lifesciences Price Performance

Shares of EW opened at $85.06 on Friday. The firm has a 50-day simple moving average of $90.13 and a two-hundred day simple moving average of $79.23. The stock has a market cap of $51.26 billion, a PE ratio of 36.66, a P/E/G ratio of 3.56 and a beta of 1.10. Edwards Lifesciences Co. has a 1-year low of $60.57 and a 1-year high of $96.12. The company has a debt-to-equity ratio of 0.08, a current ratio of 3.75 and a quick ratio of 2.67.

Edwards Lifesciences (NYSE:EW) last released its quarterly earnings results on Thursday, April 25th. The medical research company reported $0.66 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.64 by $0.02. The business had revenue of $1.60 billion for the quarter, compared to the consensus estimate of $1.58 billion. Edwards Lifesciences had a net margin of 23.01% and a return on equity of 22.86%. As a group, analysts forecast that Edwards Lifesciences Co. will post 2.77 EPS for the current year.

Wall Street Analyst Weigh In

A number of analysts have recently weighed in on EW shares. Mizuho boosted their target price on shares of Edwards Lifesciences from $95.00 to $105.00 and gave the stock a “buy” rating in a report on Thursday, April 11th. Bank of America upgraded shares of Edwards Lifesciences from a “neutral” rating to a “buy” rating in a report on Thursday, March 7th. OTR Global upgraded shares of Edwards Lifesciences from a “mixed” rating to a “positive” rating in a report on Tuesday, March 26th. StockNews.com upgraded shares of Edwards Lifesciences from a “hold” rating to a “buy” rating in a report on Monday. Finally, Oppenheimer boosted their target price on shares of Edwards Lifesciences from $93.00 to $100.00 and gave the stock an “outperform” rating in a report on Monday, March 18th. One equities research analyst has rated the stock with a sell rating, six have given a hold rating and eleven have issued a buy rating to the company’s stock. According to MarketBeat, Edwards Lifesciences currently has an average rating of “Moderate Buy” and an average target price of $92.71.

Institutional Investors Weigh In On Edwards Lifesciences

Several large investors have recently added to or reduced their stakes in the business. Commonwealth Equity Services LLC boosted its stake in Edwards Lifesciences by 7.3% during the 3rd quarter. Commonwealth Equity Services LLC now owns 163,984 shares of the medical research company’s stock worth $11,361,000 after purchasing an additional 11,117 shares during the period. Cambridge Investment Research Advisors Inc. boosted its stake in Edwards Lifesciences by 2.6% during the 3rd quarter. Cambridge Investment Research Advisors Inc. now owns 39,392 shares of the medical research company’s stock worth $2,729,000 after purchasing an additional 1,011 shares during the period. Robeco Institutional Asset Management B.V. boosted its stake in Edwards Lifesciences by 2.3% during the 3rd quarter. Robeco Institutional Asset Management B.V. now owns 554,342 shares of the medical research company’s stock worth $38,405,000 after purchasing an additional 12,449 shares during the period. Xponance Inc. boosted its stake in Edwards Lifesciences by 1.6% during the 3rd quarter. Xponance Inc. now owns 141,163 shares of the medical research company’s stock worth $9,780,000 after purchasing an additional 2,273 shares during the period. Finally, Dakota Wealth Management boosted its stake in Edwards Lifesciences by 6.5% during the 3rd quarter. Dakota Wealth Management now owns 13,324 shares of the medical research company’s stock worth $923,000 after purchasing an additional 815 shares during the period. 79.46% of the stock is owned by hedge funds and other institutional investors.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.